AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (Euronext, Nasdaq: CRXL) and San Diego, California-based Applied Molecular Evolution, Inc., (AME) (AMEV) announced that they have signed a nonexclusive, worldwide PER.C6 research license agreement allowing AME to evaluate the production of monoclonal antibodies on the PER.C6 human cell line.
AME also has an option for a nonexclusive, worldwide commercial product license to manufacture one or more specified monoclonal antibody products on the PER.C6 cell line.
Additionally, Crucell has granted AME the right to enter into collaborations with third parties for the research and development of monoclonal antibody products ...
Source: HighBeam Research, Monoclonal antibody production agreement signed.(Brief Article)